ResoTher Pharma A/S: Financial statements 2024
CVR: 37852406
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ResoTher Pharma A/S (CVR 37852406) has filed annual accounts for 2024. In 2024, the company reported a net result of DKK -10,071,000. Equity in the 2024 report amounted to DKK 12,122,000. The solvency ratio was 81.6%.
- Profit/Loss
- DKK -10,071,000
- Equity
- DKK 12,122,000
- Total Assets
- DKK 14,847,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | - | -10.1M | 12.1M | - |
| 2023 | - | - | - | 20.8M | 2 |
| 2022 | - | - | -27.2M | 12.2M | 3 |
| 2021 | - | - | -11.7M | 38.6M | 3 |
| 2020 | - | - | -5.2M | -560K | 2 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ResoTher Pharma A/S has published its annual report for 2023.
About ResoTher Pharma A/S
ResoTher Pharma A/S is a Danish company of the type Aktieselskab based in Holte, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ResoTher Pharma ApS. The management consists of Anders Kronborg. The board consists of Rebecca Anne Morison (chair), Henrik Stage, Jeppe Øvli Øvlesen and Michael Østerlund Madsen. The company is owned by Quantass ApS and TJ Biotech Holding ApS. The company has 4 employees (2026). Equity in the 2025 report amounted to DKK 12,132,000.